Andere talen Candel Therapeutics, Inc.

Aandelen

CADL

US1374041093

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,9 ^USD	+3,25%		+14,10%	+505,44%

30/05	FDA kent CAN-3110 van Candel Therapeutics de status van weesgeneesmiddel toe voor de behandeling van terugkerend hooggradig glioom	MT
23/05	Candel Therapeutics meldt verlengde totale overleving in fase 2 klinische studie met Can-2409 voor gevorderde niet-kleincellige longkanker bij patiënten die niet reageren op behandeling met immuuncheckpointremmers op de jaarlijkse Asco-bijeenkomst in 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma	30/05
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting	23/05
Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Sector Update: Health Care Stocks Decline Thursday Afternoon	11/04
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	11/04
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	09/04
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell	05/04
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday	05/04
Top Premarket Gainers	05/04
Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial	05/04
Top Midday Gainers	04/04
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	04/04
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	28/03
Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate	05/03
Sector Update: Health Care Stocks Decline Late Afternoon	13/02
Sector Update: Health Care	13/02
Candel Therapeutics Gets FDA Fast Track Label For Treatment of Recurrent High-Grade Glioma	13/02
Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma	13/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Candel Therapeutics, Inc.

Aandelen

CADL

US1374041093

Andere talen

Filters